Pages that link to "Q34467271"
Jump to navigation
Jump to search
The following pages link to A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib (Q34467271):
Displaying 50 items.
- Alterations of the intracellular peptidome in response to the proteasome inhibitor bortezomib (Q21090814) (← links)
- A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells (Q24622083) (← links)
- Discovery and characterization of a marine bacterial SAM-dependent chlorinase (Q24652817) (← links)
- Novel strategies to target the ubiquitin proteasome system in multiple myeloma (Q26773246) (← links)
- Deep sea as a source of novel-anticancer drugs: update on discovery and preclinical/clinical evaluation in a systems medicine perspective (Q26776294) (← links)
- The 26S proteasome is a multifaceted target for anti-cancer therapies (Q26795764) (← links)
- New molecular targets in mantle cell lymphoma (Q26821766) (← links)
- Detection of ubiquitin-proteasome enzymatic activities in cells: application of activity-based probes to inhibitor development (Q26823930) (← links)
- DangER: protein ovERload. Targeting protein degradation to treat myeloma (Q26825417) (← links)
- Advances in the understanding of mechanisms and therapeutic use of bortezomib (Q26849940) (← links)
- Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunit (Q27663486) (← links)
- Optimization of a series of dipeptides with a P3 threonine residue as non-covalent inhibitors of the chymotrypsin-like activity of the human 20S proteasome (Q27664692) (← links)
- Incorporation of Non-natural Amino Acids Improves Cell Permeability and Potency of Specific Inhibitors of Proteasome Trypsin-like Sites (Q27675903) (← links)
- Homopiperazine derivatives as a novel class of proteasome inhibitors with a unique mode of proteasome binding (Q27677425) (← links)
- New investigational drugs with single-agent activity in multiple myeloma (Q28071551) (← links)
- Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling (Q28082335) (← links)
- Trial Watch: Proteasomal inhibitors for anticancer therapy (Q28082910) (← links)
- Pathophysiological processes in multiple sclerosis: focus on nuclear factor erythroid-2-related factor 2 and emerging pathways (Q28235168) (← links)
- A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance (Q28395203) (← links)
- Marine actinomycetes: a new source of compounds against the human malaria parasite (Q28472855) (← links)
- From bench to bedside: lessons learned in translating preclinical studies in cancer drug development (Q28533949) (← links)
- Actinomycetes from Red Sea sponges: sources for chemical and phylogenetic diversity (Q28658500) (← links)
- Deubiquitinases (DUBs) and DUB inhibitors: a patent review (Q28834608) (← links)
- Management of Mantle Cell Lymphoma: Key Challenges and Next Steps (Q30452150) (← links)
- Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. (Q30490975) (← links)
- Patented small molecule inhibitors in the ubiquitin proteasome system (Q33307875) (← links)
- Role of proteasomes in disease (Q33307877) (← links)
- Proteasome inhibition reduces donor-specific antibody levels (Q33383491) (← links)
- Targeting the UPS as therapy in multiple myeloma (Q33384287) (← links)
- The UPS: a promising target for breast cancer treatment. (Q33384289) (← links)
- Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo (Q33394535) (← links)
- Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells (Q33453188) (← links)
- Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia. (Q33482818) (← links)
- Discovery of novel proteasome inhibitors using a high-content cell-based screening system (Q33521189) (← links)
- On to the road to degradation: atherosclerosis and the proteasome (Q33554513) (← links)
- Proteasome inhibitors in glioblastoma (Q33598931) (← links)
- Discovery and development of the anticancer agent salinosporamide A (NPI-0052). (Q33622960) (← links)
- Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma (Q33627051) (← links)
- Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1 (Q33627312) (← links)
- Differential Effects of the Proteasome Inhibitor NPI-0052 against Glioma Cells. (Q33655371) (← links)
- Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib). (Q33742779) (← links)
- Generating a generation of proteasome inhibitors: from microbial fermentation to total synthesis of salinosporamide a (marizomib) and other salinosporamides (Q33836952) (← links)
- Epidermal growth factor receptor vIII expression in U87 glioblastoma cells alters their proteasome composition, function, and response to irradiation (Q33880422) (← links)
- In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells (Q33902726) (← links)
- Chronic inflammation and cancer: potential chemoprevention through nuclear factor kappa B and p53 mutual antagonism (Q34079481) (← links)
- Discovery of a potent and highly β1 specific proteasome inhibitor from a focused library of urea-containing peptide vinyl sulfones and peptide epoxyketones (Q34079904) (← links)
- BAX/BAK-independent mitoptosis during cell death induced by proteasome inhibition? (Q34082489) (← links)
- Development of practical methodologies for the synthesis of functionalized benzoboroxoles (Q34099863) (← links)
- A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma (Q34134986) (← links)
- Salinosporamide Natural Products: Potent 20 S Proteasome Inhibitors as Promising Cancer Chemotherapeutics (Q34142223) (← links)